PerkinElmer, a global leader committed to innovating for a healthier world, today announced that its Horizon Discovery CHOSOURCE™ CHO-K1GS knockout cell line licensed by Trinomab Biotech. Co., Ltd. (www.trinomab.com), of Guangzhou, China was used to help produce and bring to clinical trial the world’s first, fully native human monoclonal neutralizing antibody (mAb) drug candidate to fight tetanus toxin.
You Might Also Like
Twist Bioscience Launches Human Methylome Panel to Enable Detection of Methylation Fractions in a Diverse Range of Applications
CST Chief Scientific Officer Roberto Polakiewicz Receives CiteAb Significant Individual Impact Award for Contributions to Scientific Rigor in Antibody Development
